Recent 8-K filings for BSEM
Highest-materiality recent filing
BioStem raises $3M private placement at $4.08/share; $10M BioTissue clearance payment due Sept 15 unpaid
- Private placement of 735,296 shares at $4.08 plus Series A and Series B warrants for 735,296 shares each at $3.83; aggregate gross proceeds ~$3.0 million; closed September 30, 2026.
- Series A warrants expire five years and Series B warrants 24 months after effectiveness of the resale registration statement; full cash exercise would add roughly $5.6 million.
-
Private placement of 735,296 shares at $4.08 plus Series A and Series B warrants for 735,296 shares each at $3.83; aggregate gross proceeds ~$3.0 million; closed September 30, 2026.
-
BioStem secures up to $40M committed equity facility with Roth Principal Investments
Facility allows BioStem to sell up to $40M shares at its discretion over a 36-month term.
-
BioStem Q2 revenue $7.9M (up 29% QoQ), net loss $9.0M, raises FY26 guide
Q2 2026 net revenue $7.9M vs $6.1M Q1 2026 (+29%) and $11.0M Q2 2025; hospital $6.7M, physician $1.1M.
-
BioStem Technologies approved for Nasdaq Capital Market listing; trading starts Aug 7
Nasdaq approved BSEM common stock for listing on The Nasdaq Capital Market on Aug 6, 2026.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.75 · Median 0.65 · Most common event other_material